MONTREAL, QUEBEC--(Marketwire - July 20, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) today announced that it has signed an analytical services contract with BioActif Inc. of Blainville, Quebec. Upon obtaining health Canada laboratory establishment license, A5 Labs will provide a comprehensive analytical and development services for BioActif. These services will include method development, raw materials and finished goods testing as well as stability studies.
"We are extremely pleased to have reached this agreement with such prestigious brand company such as BioActif. BioActif's selection of our services is a terrific endorsement of our capabilities including complex analytical procedures and stability studies, and it is another significant step in establishing A5 Labs as a premium world class CRO and Biotechnology company," said Dr. Richard Azani, President and CEO.
About A5 Labs:
A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
About BioActif:
BioActif (www.Bio-Actif.com) owns, markets and distributes some of the most respected premium brands of pharmaceutical, cosmetics and neutraceutical products throughout Quebec. The company's premium brands include Phytobec, Flex-O-Flex, Foratol, Bronchosyl, among several others.
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
